Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP&Pres, Periph Intervent | February 24, 2025 | February 25, 2025 |
| CONMED CorpCNMD · Entity 4691 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,766 |
Ending reported balance
After 2025-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-24 · Sale · Disposed 4,675 · Balance 28,454 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Row 2 · 2025-02-25 · Sale · Disposed 2,688 · Balance 25,766 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024.
CONMED Corp
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-07-01 | Direct | 5,603 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 5,603 · Balance 5,603 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2022 Filed Apr 21, 2022 20:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,645 | $46.50 | $448,492.50 |
DisclosureSEC source: 0001225208-22-005987 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,316 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 20:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 10,989 | $45.50 | $499,999.50 |
DisclosureSEC source: 0001225208-22-005929 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,961 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 11,236 | $44.50 | $500,002.00 |
DisclosureSEC source: 0001225208-22-004996 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,950 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003863 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 624 | $44.17 | $27,562.08 |
DisclosureSEC source: 0001225208-22-003863 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,186 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003863 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 17,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003296 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,439 Underlying: Common Stock · 17,439 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003082 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,804 Underlying: Common Stock · 2,804 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 859 | $42.55 | $36,550.45 |
DisclosureSEC source: 0001225208-22-003082 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,773 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003082 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · derivative · entry 6 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,634 Underlying: Common Stock · 2,816 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 862 | $42.55 | $36,678.10 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,828 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 3,333 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,020 | $42.83 | $43,686.60 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,874 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002922 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 33,970 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,970 Underlying: Common Stock · 33,970 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 11,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,880 Underlying: Common Stock · 11,880 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,031 Underlying: Common Stock · 2,030 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 622 | $44.01 | $27,374.22 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,561 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 6,840 | $43.54 | $297,806.08 |
DisclosureSEC source: 0001225208-22-000471 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,153 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.23 to $43.80, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 10,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000114 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,105 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,265 | $42.48 | $138,697.20 |
DisclosureSEC source: 0001225208-22-000114 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,993 Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 10,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000114 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014510 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 649 shares Expires 2023-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 296 | $39.46 | $11,680.16 |
DisclosureSEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,153 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| August 31, 2021 Filed Dec 6, 2021 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,800 Read SEC document |
| August 30, 2021 Filed Dec 6, 2021 21:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,935 Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 00:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 6,748 | $45.22 | $305,144.56 |
DisclosureSEC source: 0001225208-21-010899 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,118 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,439 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-21-007238 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,439 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 48,439 | $43.98 | $2,130,347.22 |
DisclosureSEC source: 0001225208-21-007238 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,158 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 48,439 | $7.39 | $357,964.21 |
DisclosureSEC source: 0001225208-21-007238 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,123 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-21-006807 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,123 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase 28,123 shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 28,123 | $40.95 | $1,151,639.66 |
DisclosureSEC source: 0001225208-21-006807 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,158 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $40.95 and $40.955. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 28,123 | $6.28 | $176,612.44 |
DisclosureSEC source: 0001225208-21-006807 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004221 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 2,037 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 929 | $38.78 | $36,026.62 |
DisclosureSEC source: 0001225208-21-004221 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,158 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004221 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 9,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · derivative · entry 7 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,981 Underlying: Common Stock · 9,981 shares Expires 2022-12-31 F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · derivative · entry 6 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,318 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,058 | $39.20 | $41,473.60 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,050 Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,608 Underlying: Common Stock · 2,804 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 969 | $38.03 | $36,851.07 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,790 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003522 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003176 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,450 Underlying: Common Stock · 2,816 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 862 | $37.52 | $32,342.24 |
DisclosureSEC source: 0001225208-21-003176 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,955 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003176 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.